摘要
目的探讨吡柔比星(THP)联合白细胞介素Ⅱ(IL-2)预防浅表膀胱癌术后复发的近期疗效.方法对37例浅表性膀胱癌患者行经尿道膀胱肿瘤电切术(TURBt)或膀胱部分切除术,术后定期用THP 30 mg+IL-2 100 000 U/40 ml做膀胱内灌注,每周1次,共8次;以后每月1次,共1年,每次药物在膀胱内保留40 min,随访结果与以往应用丝裂霉素C(MMC)的病例进行比较和讨论.结果随访10～24个月,7例复发,无瘤率为81.1%(30/37).THP+IL-2组与MMC组(40 mg)相比差异无显著性(P>0.05).结论 THP联合IL-2用于临床膀胱灌注预防浅表膀胱癌术后复发效果好,不良反应少,给药方便,值得临床推广应用.
Objective To evaluate the early efficacy of instillation of pirarubicin （THP） combined with IL-2 in prevention of postoperative recurrence of superficial bladder cancer. Methods Transurethral resection or partial cystectomy was performed on 37 patients with superficial bladder cancer, followed by THP ＋ IL-2 intravesical instillation once a week for 8 weeks and then once a month until 1 year after surgery. Results All patients have followed up 10 to 24 months, the tumor-free recurrence rate was 81.1%. This method was of less side effects. Conclusion Intravesieal instillation of pirarubicin （THP） combined with IL-2 is effective for prevention of postoperatic recurrence of superficial bladder cancer with less side effect and easy to use ,so it can be widely used in such patients.
出处
《中国肿瘤临床与康复》
2005年第6期564-566,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
